Non-Small Cell Lung Cancer Drugs Market Size 2024-2028

The non-small cell lung cancer (NSCLC) drugs market is poised for significant growth, with a forecasted increase of USD 21.06 billion at a compound annual growth rate (CAGR) of 10.87% between 2023 and 2028. This surge is driven by a combination of rising NSCLC prevalence, the approval of combination therapies, and ongoing pharmaceutical innovations aimed at combating the disease.

For more details about the industry, get the PDF sample report for free

Market Segmentation

The NSCLC drugs market is segmented into types, products, and geography. The detailed segment analysis, with data from 2018-2022, includes:

By Type:

Adenocarcinoma
Squamous cell carcinoma
Large cell carcinoma

By Product:

Biologics
Small molecule targeted therapy
Chemotherapy

By Geography:

North America
- US
- Canada
Europe
- Germany
- UK
Asia
- China
Rest of World (ROW)

By Type Insights:

The adenocarcinoma segment is expected to experience significant growth during the forecast period. Adenocarcinoma primarily develops in glandular tissue, affecting organs such as the lungs, esophagus, and stomach. Smoking, environmental toxins, and prior radiation therapy are key risk factors. Advances in deep learning systems for CT scan analysis and the development of therapies like Moderna's mRNA and Rain Therapeutics' anti-TIM-3 antibody are promising areas of innovation.

Regional Market Trends

North America:
- The region is expected to contribute 38% to the global market growth between 2023 and 2028. The increase in NSCLC cases in the US and Canada, driven by smoking and air pollution, is a key factor. Major pharmaceutical companies such as Merck KGaA, Eli Lilly and Company, Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, and Bristol-Myers Squibb Company are leading the market with high-priced, effective drugs and patient assistance programs.

Get more details by ordering the complete report

Market Dynamics

Drivers:
- The increasing prevalence of NSCLC is the primary driver of market growth. In 2023, the US is expected to see 238,340 new cases of lung cancer, with around 30,000 diagnoses in Canada, further highlighting the critical need for effective treatment.
Trends:
- The approval and introduction of combination therapies are emerging as key trends. In January 2023, Merck KGaA received US FDA approval for KEYTRUDA as a neoadjuvant treatment for resectable NSCLC in combination with chemotherapy. This development expands KEYTRUDA’s indications to six, covering both metastatic and earlier stages.
- Novartis AG is also advancing its NSCLC treatment pipeline with the Phase III CANOPY-A study of canakinumab, an IL-1β inhibitor, combined with docetaxel chemotherapy.
Challenges:
- A significant challenge to market growth is the high cost of NSCLC treatments. Drugs like vinorelbine and cisplatin, commonly used for NSCLC, have high price ranges, contributing to the overall cost burden. These costs could limit patient accessibility, although advancements in treatment options continue to offer hope.